Krishna Institute of Medical Sciences Ltd (KIMS) is currently trading at 744.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

KIMS Hospitals operates a multi-specialty hospital network focused on affordable tertiary and quaternary healthcare, offering more than 40 specialties across Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka. Its clinical portfolio includes cardiac sciences, oncology, neurosciences, renal care, orthopaedics, organ transplantation, gastroenterology, and mother-and-child care, supported by advanced technology and critical-care infrastructure. The company delivered strong operating momentum in Q2 FY27, with operating revenue rising 39.9% year-on-year to Rs 13,444 million and EBITDA increasing 34.0% to Rs 2,789 million. Growth was driven by higher inpatient and outpatient volumes, a 14.9% increase in ARPOB, and contributions from recently launched and acquired hospitals across multiple states. Expansion is progressing faster than mature-hospital monetisation: group H1 FY27 capacity reached 7,459 beds, but occupancy remained 51.8%. This creates substantial operating leverage if new facilities ramp successfully, although Karnataka remained EBITDA negative and Telangana’s occupancy declined year-on-year despite the group’s overall revenue acceleration. A notable strategic differentiator is the company’s concentration in complex clinical care, including robotic surgery, transplantation, ECMO, advanced neurosurgery, and minimally invasive procedures. New hospitals are rapidly adding capabilities such as liver and kidney transplantation, robotic surgery, oncology, and advanced cardiac care, supporting premiumisation and referral-led growth. Profitability remains mixed beneath the strong EBITDA performance. H1 FY27 EBITDA rose 27.2%, but PBT and PAT declined 22.5% and 28.0%, respectively, partly reflecting higher depreciation, financing or integration-related effects, and fair-value items; Q2 profitability recovered sharply sequentially but PAT growth was only 5.1% year-on-year.

Over the past 52 weeks, Krishna Institute of Medical Sciences Ltd has traded between a low of ₹575.55 and a high of ₹858.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Krishna Institute of Medical Sciences Ltd has a market capitalization of approximately 30,681.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Krishna Institute of Medical Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 157.58 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 30,681.47 Cr, Krishna Institute of Medical Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Krishna Institute of Medical Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Krishna Institute of Medical Sciences Ltd is 157.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Krishna Institute of Medical Sciences Ltd disclosed that it had enclosed an investor presentation with the BSE and NSE. The presentation relates to audited standalone and consolidated results for the quarter and year ended March 31, 2026.

KIMS Hospitals reported total income of ₹1,363 crore for the quarter ended September 30, 2026. This was 39.9% higher than ₹964.9 crore reported in the corresponding quarter of FY26.

KIMS has approved the acquisition of up to a 51% equity stake in Sarvottam Health Care Private Limited, Kakinada.

KIMS reported consolidated revenue from operations of ₹11,795 million for the quarter ended June 30, 2026, up 35% year-on-year.